---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089263"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:47:52.137415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q2 revenue $147M (+36% YoY), raises 2024 guidance; key FDA agreements advance pipeline

## Summary
- Q2 total revenue $147M (Crysvita $114M, Dojolvi $19M); net loss narrows to $132M from $160M.
- 2024 revenue guidance raised to $530-550M (prev $500-530M); Crysvita expected towards upper end of $375-400M.
- Cash $874M after June equity offering of $381M net; 2024 operating cash use guided below $400M.
- FDA agrees CSF heparan sulfate as surrogate endpoint for UX111 Sanfilippo accelerated approval; BLA filing late-2024/early-2025.
- Positive Phase 3 data for DTX401 in GSDIa (41.3% reduction in cornstarch, p<0.0001); Phase 2/3 OI setrusumab shows 67% fracture reduction.

## SEC filing metadata
- accession: 0000950170-24-089263
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/0000950170-24-089263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024089263/rare-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089263
- JSON: https://secwatch.observer/filing/0000950170-24-089263.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.